Morepen Laboratories Ltd Stock Price Today (NSE: MOREPENLAB)
Fundamental Score
Morepen Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Morepen Laboratories Ltd share price today is ₹41.76, down 0.33% on NSE/BSE as of 20 April 2026. Morepen Laboratories Ltd (MOREPENLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.38K (Cr). The 52-week high for MOREPENLAB share price is ₹70.50 and the 52-week low is ₹33.05. At a P/E ratio of 31.50x, MOREPENLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.78% and a debt-to-equity ratio of 0.13.
Morepen Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Institutional Deep-Dive
Bull Run Research Hub
Morepen Laboratories Share Price: A ROCE Efficiency Analysis
The pharmaceutical industry is currently experiencing a period of intense scrutiny regarding pricing pressures and regulatory hurdles, necessitating a laser focus on operational efficiency. This analysis examines the financial health of Morepen Laboratories Ltd, with a particular emphasis on Return on Capital Employed (ROCE). Currently, the Morepen Laboratories share price stands at ₹36.689999, with a Price-to-Earnings (PE) ratio of 31.5 and a ROCE of 15.08%.
ROCE, a key metric for evaluating profitability relative to capital employed, indicates how effectively Morepen Laboratories is utilizing its resources to generate profits. A ROCE of 15.08% suggests a moderate level of efficiency. To put this in perspective, we must consider sector peers like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd. While a direct comparison requires deeper data on competitor ROCE, a lower ROCE than peers might signal inefficiencies in capital allocation or operational processes.
A company's ROCE directly influences its economic moat – its ability to sustain a competitive advantage over the long term. A consistently high ROCE, driven by factors such as efficient manufacturing, strong pricing power, or robust supply chain management, strengthens this moat. Conversely, a fluctuating or declining ROCE can erode this advantage, making the company more vulnerable to competition. One can draw inferences regarding the management quality by looking at how efficiently companies like
Mankind Pharma Ltd allocate capital in comparision to Morepen Laboratories Ltd.The PE ratio of 31.5, while standard alone does not give a picture, it is important to compare to the sector average and peers to gauge overall valuation. Further investigation is needed to understand why investors are paying a premium (or discount) for Morepen Laboratories compared to its earnings. Factors like growth expectations, risk perception, and investor sentiment all contribute to this valuation. This financial analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, designed to provide a structured observational view of Morepen Laboratories' financial performance. This analysis offers an observational view only and does not constitute financial advice.
Morepen Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹35.85 | ₹38.27 | ₹35.17 | ₹37.81 | 38.17L (Cr) | |
| ₹34.56 | ₹37.40 | ₹34.56 | ₹37.20 | 55.72L (Cr) | |
| ₹35.03 | ₹35.96 | ₹33.05 | ₹33.68 | 41.40L (Cr) | |
| ₹36.50 | ₹36.99 | ₹35.30 | ₹36.15 | 55.12L (Cr) | |
| ₹36.85 | ₹37.88 | ₹35.99 | ₹36.97 | 31.58L (Cr) | |
| ₹36.49 | ₹37.23 | ₹35.20 | ₹36.55 | 32.55L (Cr) | |
| ₹36.59 | ₹36.75 | ₹35.10 | ₹35.33 | 33.30L (Cr) | |
| ₹37.60 | ₹38.19 | ₹36.80 | ₹36.99 | 25.37L (Cr) | |
| ₹38.25 | ₹38.25 | ₹36.91 | ₹37.04 | 23.84L (Cr) | |
| ₹38.30 | ₹39.30 | ₹38.08 | ₹38.63 | 28.28L (Cr) |
Morepen Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹34.56 | ₹38.27 | ₹34.56 | ₹37.81 | +9.40% | |
| ₹41.10 | ₹43.25 | ₹33.05 | ₹33.68 | -18.05% | |
| ₹36.63 | ₹48.84 | ₹34.83 | ₹43.67 | +19.22% | |
| ₹41.07 | ₹42.44 | ₹33.50 | ₹36.31 | -11.59% | |
| ₹43.60 | ₹44.40 | ₹38.42 | ₹41.07 | -5.80% | |
| ₹47.60 | ₹48.48 | ₹42.49 | ₹43.40 | -8.82% | |
| ₹48.13 | ₹50.38 | ₹47.51 | ₹47.58 | -1.14% | |
| ₹46.63 | ₹55.50 | ₹46.63 | ₹47.85 | +2.62% | |
| ₹58.50 | ₹59.34 | ₹45.28 | ₹46.63 | -20.29% | |
| ₹62.03 | ₹66.40 | ₹57.00 | ₹58.45 | -5.77% | |
| ₹65.00 | ₹70.50 | ₹59.71 | ₹61.77 | -4.97% | |
| ₹60.60 | ₹68.40 | ₹54.89 | ₹64.84 | +7.00% |
AI Research Briefing
Powered by Gemini · 2026-04-15
Morepen's CDMO story hinges on flawless execution of its large contract and securing new deals, a risky proposition given its small-cap status and negative free cash flow.
⚡WHAT'S HAPPENING NOW (last 2-4 weeks):
No major catalysts found after live search. The India Pharma 2026 conference concluded on April 15, 2026, with discussions on strengthening the pharma ecosystem.
�� CORE STORY (THE REAL GAME):
Morepen is a CDMO play, riding the wave of global pharma companies outsourcing manufacturing to reduce costs and diversify supply chains. The market is pricing in continued growth in CDMO revenues and margin expansion.
- ₹825 crore CDMO contract win
- Q3FY26 profit increase of 3%
- Positive sentiment from India Pharma 2026
- New CDMO contract wins
- Faster-than-expected execution of existing contract
- API price stabilization
- Small-cap liquidity risk
- Negative free cash flow
- Execution risk on CDMO contract
FII decreased holdings by 0.1%. DII decreased holdings by 0.01%. Promoter holding steady.
India Pharma 2026 highlights the push for enhanced funding and infrastructure for the pharma sector.
₹825 crore multi-year CDMO contract from a global pharmaceutical company.
No. Free Cash Flow 5Y: ₹-444.19 Cr
Next 3-6 months depend on CDMO execution. Watch for revenue recognition and margin impact. Key is new contract wins to sustain growth.
Primary Thesis Risk
Failure to execute the CDMO contract will lead to a significant derating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Morepen Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Shareholding Pattern
Promoter
FII
DII
Pledged
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Morepen Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MOREPENLAB across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (15.08%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Consistent Growth Track Record (16.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (23.60% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (28.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.13)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-49.02%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-5.97%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-444.19 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Peer Comparison - Pharmaceuticals
Compare Morepen Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Morepen Laboratories LtdMorepen Laborat...Selected✓ MOREPENLAB • 500288 | 34.5/100 | ₹41.76₹42 | ₹2379.21₹2379.21 | 31.50Average 31.5 Average | 11.78%Average 11.78% Average | 15.08%Good 15.08% Good | 0.13Excellent 0.1 Excellent | 28.58%Excellent 28.58% Excellent | 16.26%Excellent 16.26% Excellent | 0.46% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1671.00₹1671 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 0.00%Poor 0.00% Poor | 0.07Excellent 0.1 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6286.50₹6287 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 0.00%Poor 0.00% Poor | 0.01Excellent 0.0 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4180.50₹4181 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 0.00%Poor 0.00% Poor | 0.33Excellent 0.3 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1237.20₹1237 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 0.00%Poor 0.00% Poor | 0.01Excellent 0.0 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1237.80₹1238 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 0.00%Poor 0.00% Poor | 0.16Excellent 0.2 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2335.10₹2335 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 0.00%Poor 0.00% Poor | 0.32Excellent 0.3 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹942.20₹942 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 0.00%Poor 0.00% Poor | 0.38Excellent 0.4 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2122.40₹2122 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 0.00%Poor 0.00% Poor | 0.55Good 0.6 Good | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1381.00₹1381 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 0.00%Poor 0.00% Poor | 0.22Excellent 0.2 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5652.00₹5652 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 0.00%Poor 0.00% Poor | 0.18Excellent 0.2 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Morepen Laboratories Ltd Financial Statements
Comprehensive financial data for Morepen Laboratories Ltd including income statement, balance sheet and cash flow
About MOREPENLAB (Morepen Laboratories Ltd)
Morepen Laboratories Ltd is a versatile pharmaceutical organization deeply rooted in the global healthcare landscape. With a firm commitment to innovation and quality, the company ...navigates a diverse portfolio encompassing the development, production, and distribution of a wide array of pharmaceutical products. From foundational Active Pharmaceutical Ingredients (APIs) that serve as building blocks for life-saving medications, to meticulously crafted branded and generic formulations, Morepen caters to varied therapeutic needs. Furthermore, their venture into home health products empowers individuals to proactively manage their well-being, reflecting a holistic approach to healthcare. This integrated structure allows Morepen to maintain a robust presence across multiple market segments, consistently striving to meet the evolving demands of patients and healthcare professionals worldwide. The company's API segment fuels the creation of essential drugs across a spectrum of therapeutic areas. Morepen produces the foundational components needed for medications addressing conditions such as allergies, respiratory ailments, high cholesterol, hypertension, diabetes, blood clotting disorders, digestive issues, and mental health disorders. Beyond APIs, Morepen formulates and markets a range of branded and generic medications, ensuring accessibility to vital treatments. This dual approach allows the company to cater to both large pharmaceutical manufacturers and individual consumers, expanding its reach and impact on global health. By consistently upholding stringent quality standards and investing in research and development, Morepen solidifies its position as a reliable supplier of essential pharmaceutical products. Morepen Laboratories extends its reach beyond prescription drugs by offering a suite of consumer-focused home health products. Recognizing the growing importance of self-monitoring and preventative care, they provide devices that allow individuals to actively manage their health from the comfort of their homes. This includes products designed to improve air quality, along with instruments for monitoring vital signs such as blood pressure and blood glucose levels. These products empower individuals to take a proactive role in their healthcare journey, fostering a sense of control and contributing to better overall health outcomes. By diversifying into the home health sector, Morepen demonstrates its commitment to providing comprehensive healthcare solutions that address a wide range of needs.
Company Details
Key Leadership
Corporate Events
MOREPENLAB Share Price: Frequently Asked Questions
What is the current share price of Morepen Laboratories Ltd?
As of 20 Apr 2026, 08:32 am IST, Morepen Laboratories Ltd share price is ₹41.76. The Morepen Laboratories Ltd stock has a market capitalisation of ₹2.38K (Cr) on NSE/BSE.
Is Morepen Laboratories Ltd share price Overvalued or Undervalued?
Morepen Laboratories Ltd share price is currently trading at a P/E ratio of 31.50x, compared to the industry average of 31.77x. Based on this relative valuation, the Morepen Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of Morepen Laboratories Ltd share price?
The 52-week high of Morepen Laboratories Ltd share price is ₹70.50 and the 52-week low is ₹33.05. These values are updated daily from NSE/BSE price data.
What factors affect the Morepen Laboratories Ltd share price?
Key factors influencing Morepen Laboratories Ltd share price include quarterly earnings growth (Sales Growth: -5.97%), raw material costs, government spending, and institutional flows (FII/DII holding).
Is Morepen Laboratories Ltd a good stock for long-term investment?
Morepen Laboratories Ltd shows a 5-year Profit Growth of 28.58% and an ROE of 11.78%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.13 before investing in Morepen Laboratories Ltd shares.
How does Morepen Laboratories Ltd compare with its industry peers?
Morepen Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare Morepen Laboratories Ltd share price P/E of 31.50x and ROE of 11.78% against the industry averages to determine competitive standing.
What is the P/E ratio of Morepen Laboratories Ltd and what does it mean?
Morepen Laboratories Ltd share price has a P/E ratio of 31.50x compared to the industry average of 31.77x. Investors pay ₹32 for every ₹1 of annual earnings.
How is Morepen Laboratories Ltd performing according to Bull Run's analysis?
Morepen Laboratories Ltd has a Bull Run fundamental score of 34.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does Morepen Laboratories Ltd belong to?
Morepen Laboratories Ltd operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Morepen Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for MOREPENLAB?
MOREPENLAB has an ROE of 11.78%, which shows decent profitability but room for improvement. ROE measures how efficiently Morepen Laboratories Ltd generates profits from shareholders capital.
How is MOREPENLAB debt-to-equity ratio and what does it indicate?
MOREPENLAB has a debt-to-equity ratio of 0.13, which indicates conservative financing with low financial risk.
What is MOREPENLAB dividend yield and is it a good dividend stock?
MOREPENLAB offers a dividend yield of 0.46%, meaning you receive ₹0.46 annual dividend for every ₹100 invested in Morepen Laboratories Ltd shares.
How has MOREPENLAB share price grown over the past 5 years?
MOREPENLAB has achieved 5-year growth rates of: Sales Growth 16.26%, Profit Growth 28.58%, and EPS Growth 23.60%.
What is the promoter holding in MOREPENLAB and why does it matter?
Promoters hold 35.65% of MOREPENLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Morepen Laboratories Ltd.
What is MOREPENLAB market capitalisation category?
MOREPENLAB has a market capitalisation of ₹2379 crores, placing it in the Small-cap category.
How volatile is MOREPENLAB stock?
MOREPENLAB has a beta of N/A. A beta > 1 suggests the Morepen Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MOREPENLAB operating profit margin trend?
MOREPENLAB has a 5-year average Operating Profit Margin (OPM) of 8.72%, indicating the company's operational efficiency.
How is MOREPENLAB quarterly performance?
Recent quarterly performance shows Morepen Laboratories Ltd YoY Sales Growth of -5.97% and YoY Profit Growth of -49.02%.
What is the institutional holding pattern in MOREPENLAB?
MOREPENLAB has FII holding of 1.62% and DII holding of 1.49%. Significant institutional holding often suggests professional confidence in the Morepen Laboratories Ltd stock.